Feb 12 (Reuters) - Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.

Shares of CymaBay were halted ahead of the announcement in premarket hours. (Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)